The TKI Era in Chronic Leukemias

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Tyrosine kinases regulate crucial cell functions like proliferation and survival.
• Dysregulated tyrosine kinase pathways are implicated in hematologic malignancies, including CML and CLL.
• Specific targets include BCR-ABL1 in CML and the B-cell receptor pathway in CLL.

Purpose of the Study:

• To review the therapeutic advancements in CML and CLL driven by tyrosine kinase inhibitors.
• To highlight the efficacy and evolving landscape of targeted therapies for these leukemias.
• To discuss the mechanisms and clinical impact of various tyrosine kinase inhibitor classes.

Main Methods:

• Review of current literature on tyrosine kinase inhibitors in CML and CLL.
• Analysis of clinical trial data for BCR-ABL1 and BTK inhibitors.
• Discussion of drug mechanisms, resistance, and side effect profiles.

Main Results:

• Multiple generations of BCR-ABL1 inhibitors (imatinib to ponatinib) and asciminib achieve deep molecular remission in CML.
• BTK inhibitors (irreversible and reversible) demonstrate significant efficacy in CLL, with pirtobrutinib addressing C481 resistance.
• PI3K inhibitors offer alternatives in CLL but face toxicity challenges.

Conclusions:

• Tyrosine kinase inhibitors have largely replaced conventional chemotherapy for CML and CLL.
• These targeted therapies are generally well-tolerated with manageable side effects.
• Tyrosine kinase inhibitors have markedly improved patient outcomes in hematologic malignancies.